Massoud Toussi1, Margarita Shlaen2, Florence Coste3, Hanka de Voogd4, Vasilis Dimos5, Sigal Kaplan6. 1. Department Real World Solutions, IQVIA, La Défense Cedex, France. 2. Department Real World Solutions, IQVIA, Munich, Germany. 3. Department Epidemiology and Risk-Benefit, Sanofi Aventis R&D, Chilly Mazarin, France. 4. Department Global Clinical Research, Mylan, Lyon, France. 5. Department Pharmacovigilance (medical section), Demo S.A., Athens, Greece. 6. Department Pharmacoepidemiology, Teva Pharmaceutical Industries Ltd, Netanya, Israel.
Abstract
PURPOSE: The purpose of this study was to evaluate the effectiveness of the risk minimisation measures (RMMs) implemented in Europe in 2014 for valproate-containing products to mitigate their risk during pregnancy and to characterise valproate prescribing patterns in women of childbearing potential (WCBP) before and after implementation of RMMs. METHODS: A multinational cohort study based on existing data sources using a pre-/post- design was performed in five European countries (France, Germany, Spain, Sweden, UK) in an outpatient setting. Effectiveness of RMMs was assessed by comparing the proportion of valproate initiations as second (or subsequent) line therapy before and after implementation of RMMs (primary outcome) with an increase in this proportion indicating success of RMMs. Overall use of valproate and incidence of pregnancies in WCBP were also examined. RESULTS: The proportion of valproate initiations as second line therapy increased after implementation of RMMs in incident female users in Sweden (from 81.1%, 95% CI 79.9%-82.3% to 84.5%, 95% CI 83.5%-85.5%) and the UK (from 66.4%, 95% CI 64.5%-68.3% to 72.4%, 95% CI 70.0%-74.9%), it remained the same in Germany and Spain and decreased in France from 48.7% (95% CI 45.6%-51.9%) to 40.6% (95% CI 37.6%-43.7%). In Sweden and the UK, the incidence of pregnancies exposed to valproate decreased in the post-implementation period: 8.0 vs 9.5 and 10.9 vs 16.9 per 1000 person-years, respectively. CONCLUSION: The results on primary outcome of this study suggest limited effectiveness of the RMMs. Additional RMMs were implemented in 2018.
PURPOSE: The purpose of this study was to evaluate the effectiveness of the risk minimisation measures (RMMs) implemented in Europe in 2014 for valproate-containing products to mitigate their risk during pregnancy and to characterise valproate prescribing patterns in women of childbearing potential (WCBP) before and after implementation of RMMs. METHODS: A multinational cohort study based on existing data sources using a pre-/post- design was performed in five European countries (France, Germany, Spain, Sweden, UK) in an outpatient setting. Effectiveness of RMMs was assessed by comparing the proportion of valproate initiations as second (or subsequent) line therapy before and after implementation of RMMs (primary outcome) with an increase in this proportion indicating success of RMMs. Overall use of valproate and incidence of pregnancies in WCBP were also examined. RESULTS: The proportion of valproate initiations as second line therapy increased after implementation of RMMs in incident female users in Sweden (from 81.1%, 95% CI 79.9%-82.3% to 84.5%, 95% CI 83.5%-85.5%) and the UK (from 66.4%, 95% CI 64.5%-68.3% to 72.4%, 95% CI 70.0%-74.9%), it remained the same in Germany and Spain and decreased in France from 48.7% (95% CI 45.6%-51.9%) to 40.6% (95% CI 37.6%-43.7%). In Sweden and the UK, the incidence of pregnancies exposed to valproate decreased in the post-implementation period: 8.0 vs 9.5 and 10.9 vs 16.9 per 1000 person-years, respectively. CONCLUSION: The results on primary outcome of this study suggest limited effectiveness of the RMMs. Additional RMMs were implemented in 2018.
Authors: Morris J Cohen; Kimford J Meador; Nancy Browning; Ryan May; Gus A Baker; Jill Clayton-Smith; Laura A Kalayjian; Andres Kanner; Joyce D Liporace; Page B Pennell; Michael Privitera; David W Loring Journal: Epilepsy Behav Date: 2013-09-05 Impact factor: 2.937
Authors: Rachel Charlton; Christine Damase-Michel; Caroline Hurault-Delarue; Rosa Gini; Maria Loane; Anna Pierini; Aurora Puccini; Amanda Neville; Julia Snowball; Joan K Morris Journal: Pharmacoepidemiol Drug Saf Date: 2019-08-26 Impact factor: 2.890
Authors: Kimford J Meador; Patricia Penovich; Gus A Baker; Page B Pennell; Edward Bromfield; Alison Pack; Joyce D Liporace; Maria Sam; Laura A Kalayjian; David J Thurman; Eugene Moore; David W Loring Journal: Epilepsy Behav Date: 2009-05-27 Impact factor: 2.937
Authors: Caroline Minassian; Rachael Williams; Wilhelmine H Meeraus; Liam Smeeth; Oona M R Campbell; Sara L Thomas Journal: Pharmacoepidemiol Drug Saf Date: 2019-06-13 Impact factor: 2.890